how are glp 1 drugs made Discovery of GLP-1–Based for the Treatment of Obesity Science's 2023 Breakthrough: GLP-1R Agonists

Here the authors report that D-allulose triggers GLP-1 release in the gut and GLP-1R signaling on vagal afferents, counteracting arrhythmic overeating, obesity and diabetes.

Understanding their distinct mechanisms, clinical evidence bases, and how genetic and biomarker data inform personalized treatment selection helps patients and providers make evidence-based decisions

GLP-1RA only reduced the risk of nonfatal stroke

Limited head-to-head studies compare established glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dipeptidyl peptidase-4 inhibitors (DPP-4is), and sodium-glucose co-transporter-2 inhibitors (SGLT-2is) to insulin in the management of uncontrolled type 2 diabetes mellitus (T2DM)

It is a monosaccharide, which means it is a single sugar molecule

Although rare, associations with nonarteritic anterior ischemic optic neuropathy, pancreatitis, medullary thyroid carcinoma, and acute kidney injury (AKI) have been reported, primarily through pharmacovigilance and case-based evidence